CR10985A - Progesterona para la prevencion de nacimiento pretermino espontaneo - Google Patents

Progesterona para la prevencion de nacimiento pretermino espontaneo

Info

Publication number
CR10985A
CR10985A CR10985A CR10985A CR10985A CR 10985 A CR10985 A CR 10985A CR 10985 A CR10985 A CR 10985A CR 10985 A CR10985 A CR 10985A CR 10985 A CR10985 A CR 10985A
Authority
CR
Costa Rica
Prior art keywords
progesterone
birth
pretermine
spontaneous
prevention
Prior art date
Application number
CR10985A
Other languages
English (en)
Inventor
George Creasy
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39301249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10985(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of CR10985A publication Critical patent/CR10985A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un metodo para tratar o prevenir nacimiento pretermino espontaneo en mujeres embarazadas y que mejora la morbilidad y mortalidad neonatal. El metodo incluye adminsitrar a una mujer embarazada en necesidad del mismo una cantidad efectiva de una progesterona suficiente para prolongar la gestacion al reducir al minimo el acortamiento o borramiento de su cervix.
CR10985A 2007-02-06 2009-08-21 Progesterona para la prevencion de nacimiento pretermino espontaneo CR10985A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88848007P 2007-02-06 2007-02-06
US97366707P 2007-09-19 2007-09-19

Publications (1)

Publication Number Publication Date
CR10985A true CR10985A (es) 2009-10-23

Family

ID=39301249

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10985A CR10985A (es) 2007-02-06 2009-08-21 Progesterona para la prevencion de nacimiento pretermino espontaneo

Country Status (23)

Country Link
US (2) US8828981B2 (es)
EP (1) EP2117554B1 (es)
JP (2) JP5580601B2 (es)
KR (1) KR101546101B1 (es)
AR (1) AR065179A1 (es)
AU (1) AU2008212724A1 (es)
BR (1) BRPI0807203A2 (es)
CA (1) CA2677354C (es)
CL (1) CL2008000375A1 (es)
CO (1) CO6220941A2 (es)
CR (1) CR10985A (es)
ES (1) ES2596803T3 (es)
GE (1) GEP20135727B (es)
IL (1) IL200272A (es)
MA (1) MA31200B1 (es)
ME (1) ME00930B (es)
MX (1) MX2009008409A (es)
MY (1) MY184866A (es)
NZ (1) NZ579114A (es)
PE (1) PE20081738A1 (es)
RU (1) RU2524617C2 (es)
TW (1) TWI471135B (es)
WO (1) WO2008096122A2 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014220A2 (en) 2002-08-13 2004-02-19 N-Dia, Inc. Devices and methods for detecting amniotic fluid in vaginal secretions
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
PL2359807T3 (pl) 2008-02-04 2017-12-29 Ferring B.V. Monolityczne pierścienie dopochwowe zawierające progesteron oraz metody ich wytwarzania i stosowania
EP2334300B1 (en) 2008-09-24 2016-02-17 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Composition and method for treatment of preterm labor
GB0905964D0 (en) * 2009-04-06 2009-05-20 King S College London Marker
US20110152840A1 (en) * 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
EP2544707B1 (en) * 2010-03-09 2018-11-21 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
WO2012058463A2 (en) * 2010-10-27 2012-05-03 Dignity Health Trimegestone (tmg) for treatment of preterm birth
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DE102012009057A1 (de) * 2012-05-09 2013-11-14 Dr. Arabin GmbH & Co. KG Rotationspessar mit zusätzlicher Wirkstoffkomponente
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
ES2761575T3 (es) 2013-01-02 2020-05-20 Qiagen Sciences Llc Métodos para predecir el tiempo hasta el parto en una mujer embarazada
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9820994B2 (en) 2014-06-28 2017-11-21 Laboratorios Andromaco S.A. Cerclage pessary containing progesterone of prolonged, sustained, and continuous release useful for prevention of preterm birth
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
KR101726488B1 (ko) 2015-02-23 2017-04-13 이화여자대학교 산학협력단 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
AU2016284459B2 (en) 2015-06-22 2021-12-23 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
WO2017040243A1 (en) * 2015-08-28 2017-03-09 Kypha, Inc. Methods for predicting flare and improving treatment of patients
WO2017059070A1 (en) 2015-09-29 2017-04-06 Amag Pharmaceuticals, Inc. Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3022693A1 (en) * 2016-05-16 2017-11-23 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
US10656164B2 (en) 2016-12-22 2020-05-19 Qiagen Sciences, Llc Screening asymptomatic pregnant woman for preterm birth
US10935555B2 (en) 2016-12-22 2021-03-02 Qiagen Sciences, Llc Determining candidate for induction of labor
JP2018140172A (ja) * 2017-02-28 2018-09-13 株式会社Ｎｔｔドコモ データ収集装置及びデータ収集方法
WO2018232289A1 (en) 2017-06-15 2018-12-20 Wiesman Holdings, LLC Device for delivery of a solution into a body orifice
RU2657772C1 (ru) * 2017-07-06 2018-06-15 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский институт акушерства и гинекологии" Министерства здравоохранения Московской области Способ профилактики гестационных осложнений у беременных с эпилепсией
US20190038637A1 (en) * 2017-08-05 2019-02-07 Eric Marchewitz Use of Hydroxyprogesterone Derivatives for Enhanced Health and Physical Performance II
MX2020004421A (es) * 2017-10-30 2020-09-25 Carmentix Pte Ltd Biomarcadores de parto prematuro.
RU2692932C2 (ru) * 2017-11-07 2019-06-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) БИОКАТАЛИЗАТОР ДЛЯ ПОЛУЧЕНИЯ 11α-АЦЕТОКСИПРОГЕСТЕРОНА
USD918388S1 (en) 2018-06-15 2021-05-04 Wiesman Holdings, LLC Solution diffusing head
JP7301326B2 (ja) * 2018-10-16 2023-07-03 公立大学法人横浜市立大学 新生児期～小児期発症の脳小血管病又はその保因者の検出方法
US12310934B2 (en) * 2019-03-20 2025-05-27 The Regents Of The University Of California Methods of treatment of spontaneous preterm birth
MX2021011885A (es) * 2019-03-29 2022-04-18 Juniper Pharmaceuticals Inc N/K/A Catalent Jnp Inc Anillos intravaginales segmentados de eva que contienen progesterona.
KR102157438B1 (ko) * 2019-04-16 2020-09-21 고려대학교 산학협력단 조산 진단 방법 및 키트
CN114728013A (zh) * 2019-09-23 2022-07-08 斯坦福大学托管董事会 延长妊娠以及月经或妊娠的并发症的治疗方法
WO2021068239A1 (zh) 2019-10-12 2021-04-15 国家卫生健康委科学技术研究所 用于黄体支持的阴道缓释给药系统及其制备方法与应用
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US12369883B2 (en) 2020-06-19 2025-07-29 Ultrasound AI, Inc. Artificial intelligence system for determining clinical values through medical imaging
US11266376B2 (en) 2020-06-19 2022-03-08 Ultrasound Ai Inc. Premature birth prediction
KR102482468B1 (ko) * 2020-08-11 2022-12-28 연세대학교 산학협력단 조산에 대한 정보 제공 방법 및 이를 적용한 디바이스
US20220072008A1 (en) * 2020-09-08 2022-03-10 Cedars-Sinai Medical Center Method of using progesterone receptor agonists for the treatment of covid-19
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery
WO2022173786A1 (en) * 2021-02-10 2022-08-18 Mirvie, Inc. Methods and systems for conducting pregnancy-related clinical trials
KR102823321B1 (ko) * 2022-01-17 2025-06-19 연세대학교 산학협력단 자궁 경부에 대한 정보 제공 방법 및 이를 이용한 자궁 경부에 대한 정보 제공용 디바이스
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
WO2026072486A1 (en) * 2024-09-25 2026-04-02 The Population Council, Inc. Nestorone® for preventing and treating preterm birth

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
DE4229820C2 (de) 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
US5830848A (en) 1992-10-09 1998-11-03 The Regents Of The University Of California Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
US5948762A (en) 1993-07-16 1999-09-07 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
CN1151781C (zh) 1995-03-14 2004-06-02 舍林股份公司 一氧化氮的供体或者一氧化氮的抑制剂调节子宫颈扩张和伸展的用途
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
US5744463A (en) * 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US5941888A (en) * 1998-02-18 1999-08-24 Target Therapeutics, Inc. Vaso-occlusive member assembly with multiple detaching points
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
MXPA02000127A (es) 1999-06-21 2003-01-28 Columbia Lab Bermuda Ltd Programacion de ovulacion.
US6375970B1 (en) * 1999-07-07 2002-04-23 Andre Bieniarz Methods and materials for preterm birth prevention
AU2002313517B2 (en) 2001-08-31 2007-09-06 Bayer Schering Pharma Oy Drug delivery system
FR2832065B1 (fr) * 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
FR2842108B1 (fr) 2002-07-09 2008-05-02 Effik Composes a base d'hormone et de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
US20040266025A1 (en) 2003-02-06 2004-12-30 Durlin Hickok Screening and treatment methods for prevention of preterm delivery
JP2008515909A (ja) 2004-10-07 2008-05-15 デュラメド ファーマシューティカルズ インコーポレーティッド 上昇用量延長サイクル療法を利用するホルモン処置の方法
AU2006249349B2 (en) 2005-05-26 2012-01-12 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth

Also Published As

Publication number Publication date
AU2008212724A1 (en) 2008-08-14
BRPI0807203A2 (pt) 2014-07-22
TWI471135B (zh) 2015-02-01
MY184866A (en) 2021-04-28
IL200272A (en) 2014-02-27
CA2677354C (en) 2015-07-07
HK1136975A1 (zh) 2010-07-16
CA2677354A1 (en) 2008-08-14
JP2014058529A (ja) 2014-04-03
CO6220941A2 (es) 2010-11-19
AR065179A1 (es) 2009-05-20
JP2010518058A (ja) 2010-05-27
US20080188829A1 (en) 2008-08-07
CL2008000375A1 (es) 2008-05-30
NZ579114A (en) 2012-07-27
KR101546101B1 (ko) 2015-08-20
EP2117554A2 (en) 2009-11-18
ES2596803T3 (es) 2017-01-12
MX2009008409A (es) 2009-09-16
KR20090123875A (ko) 2009-12-02
WO2008096122A2 (en) 2008-08-14
EP2117554B1 (en) 2016-07-13
RU2524617C2 (ru) 2014-07-27
US8828981B2 (en) 2014-09-09
US7884093B2 (en) 2011-02-08
ME00930B (me) 2012-03-20
MA31200B1 (fr) 2010-02-01
PE20081738A1 (es) 2008-11-20
JP5580601B2 (ja) 2014-08-27
WO2008096122A3 (en) 2009-02-26
IL200272A0 (en) 2010-04-29
RU2009133315A (ru) 2011-03-20
TW200902030A (en) 2009-01-16
US20090264395A1 (en) 2009-10-22
GEP20135727B (en) 2013-01-25

Similar Documents

Publication Publication Date Title
CR10985A (es) Progesterona para la prevencion de nacimiento pretermino espontaneo
ECSP20066233A (es) Compuestos y sus usos para aliviar síntomas asociados a la menopausia
MX2017001738A (es) Vitamina b2 para la diabetes gestacional.
DOP2012000290A (es) 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario
NI202000070A (es) Compuestos y sus usos para aliviar síntomas asociados a la menopausia
MX2015016038A (es) Agente terapéutico y método de uso.
GT201200012A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimiento para su preparacion y su uso para el tratamiento de enfermedades
MX2017008455A (es) Tratamiento con antagonista del receptor de oxitocina en la fase lutea para la implatacion y embarazo en mujeres sometidas a tratamiento con tecnologias de reproduccion asistida.
BR112014026340A2 (pt) sandália para hálux valgo
CO2020000526A2 (es) Composición para su uso en la prevención y el traramiento de patologías del aparato cardiovascular
BR112016026510A2 (pt) Dispositivo e formulação para tratamento tópico da dor que afeta a área vulvar do órgão genital feminino
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
American College of Obstetricians and Gynecologists ACOG Committee Opinion No. 427: misoprostol for postabortion care
BR112014030984A2 (pt) composições e métodos para aumentar a eficácia de microbicidas contraceptivos
PH12015502160A1 (en) Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women
UA101474C2 (ru) Применение прогестерона для производства лекарственного средства
CO2017007689A2 (es) Composiciones y métodos que utilizan il-8 para aumentar la producción de leche y mejorar la salud reproductiva e inhibir la hipercetonemia en mamíferos
AR057755A1 (es) Metodo para tratar mamiferos placentarios parturientos con el fin de reducir el agotamiento materno y/o uterino
BR112015015370A2 (pt) uso de uma combinação de sal e açúcar na fabricação de um medicamento utilizado para tratar a síndrome da vagina relaxada ou doença colpoxerose em um mamífero
AR114799A1 (es) Compuestos y sus usos para aliviar los síntomas relacionados con la menopausia
Silva et al. PREGNANCY OUTCOME IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE): A BRAZILIAN MULTICENTER COHORT STUDY
UA41294U (ru) Способ лечения синдрома ашермана у женщин репродуктивного возраста
Ayati Nausea: case report
RU2010130718A (ru) Способ гормональной терапии для ревитализации женщин
CU20080067A7 (es) Método para la anticoncepción hormonal preventiva bajo demanda